Sanofi's on­col­o­gy R&D group marks a pair of set­backs on isat­ux­imab/Lib­tayo com­bo as can­cer stud­ies fiz­zle out

Sanofi’s can­cer R&D group has suf­fered a set­back with the fail­ure of a pair of clin­i­cal tri­als match­ing their CD38 con­tender isat­ux­imab with Re­gen­eron’s PD-1 check­point Lib­tayo (cemi­plimab) for non-small cell lung as well as prostate can­cers.

All we know from the phar­ma gi­ant is con­tained in a brief men­tion of the bur­ial in their Q3 re­port out Thurs­day, not­ing that the com­bi­na­tion stud­ies were iced af­ter in­ves­ti­ga­tors found that they had fiz­zled on the ef­fi­ca­cy side. Safe­ty was not an is­sue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER